Midatech Pharma wins approval to commence tumour treatment study

Fri, 20th Sep 2019

Midatech Pharma said it had received approval to commence a study of a treatment for acromegaly and neuroendocrine tumours. The Phase 1 study would test its treatment candidate MTD201 and investigate subcutaneous administration as an additional injection route, compared to intramuscular administration. It would be conducted in 28 healthy subjects, with data expected to become available towards the end of 2019 or early in 2020. The objective was to determine the administration route for the pivotal registration study to be commenced in 2020. At 8:31am: (LON:MTPH) Midatech Pharma Plc share price was +0.83p at 6.2p Story provided by StockMarketWire.com

FTSE 100 Latest
Value7,336.25
Change-14.96